Aimei Health Technology Co., Ltd.
Aimei Health Technology Co., Ltd. is a blank check company formed to complete a merger, share exchange, asset acquisition, share purchase, recapitalization, or similar business combination. It has not yet generated operating revenue and has not identified a specific operating business beyond its announced proposed combination with United Hydrogen Group Inc. The company’s current activity is centered on holding IPO proceeds in trust, maintaining public-company compliance, and negotiating a transaction that would transform it into an operating business. Until a business combination closes, its value is driven by the quality of the target, the structure of the deal, and the amount of cash available in trust.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenue{"• Special purpose acquisition company (SPAC) structure","• IPO proceeds held in trust for a future business combination","• Merger and acquisition transaction execution","• Public-company listing and shareholder approval process","• Sponsor-backed private placement units"}
IPO units, over-allotment proceeds, and sponsor private placement units used to fund the search for a target.
Cash and short-term U.S. government securities held in trust for public shareholders until a transaction closes or funds are returned.
Negotiation, documentation, shareholder approval, and closing of a merger or similar acquisition transaction.
SEC reporting, legal, accounting, auditing, and due diligence activities required of a listed blank check company.
Customers
Aimei Health does not sell products or services to end customers in the normal operating sense; its current counterparties are investors, the sponsor, underwriters, and the target company in the proposed business combination. Public shareholders provide the IPO capital and hold redeemable interests tied to the eventual transaction outcome. Aimei Investment Ltd. is the sponsor-side investor that purchased private placement units and supports the SPAC structure. The proposed target, United Hydrogen Group Inc., is the operating business that would become the combined company if the merger closes.
Investors who bought IPO units and rights and are effectively financing the search for and closing of a future business combination.
Aimei Investment Ltd. purchased private units to provide additional capital and align sponsor interests with the transaction process.
United Hydrogen Group Inc. is the operating business being acquired through the announced merger and is central to the company’s future value.
Banks, legal counsel, auditors, and other advisors support the IPO, compliance, and transaction execution.
Strategy
The company’s strategy is to complete an initial business combination and transition from a blank check vehicle into an operating business. Its disclosed path is the proposed merger with United Hydrogen Group Inc., which would provide the post-combination operating platform. Management must preserve shareholder support, satisfy closing conditions, and manage the timing risk embedded in the merger agreement. Until closing, the company’s strategic focus is on transaction execution, regulatory compliance, and maintaining sufficient liquidity to complete the deal process.
The company has no operating business until a business combination closes, so transaction completion is the core value-creation event.
The company must preserve cash and manage public-company costs while the deal process is pending.
If the merger closes, the combined company will need a functioning governance, reporting, and capital structure.
Geography
Aimei Health is incorporated as a Cayman Islands exempted company, while its trust account is located in the United States. The company’s current capital structure and public listing are U.S.-based, but the announced merger counterparty includes Cayman Islands entities, reflecting a cross-border SPAC transaction structure. Management states that it is not limited to any particular industry or geographic region when searching for a target. Because the company has no operating revenue yet, geography currently matters mainly through legal domicile, trust-account location, and the jurisdictional structure of the proposed merger.
Risks
The company’s main risk is execution risk around the proposed business combination, because failure to satisfy closing conditions or obtain shareholder approval would leave it without an operating business. Timing risk is also material: the merger agreement includes a deadline and customary termination rights, so delays can jeopardize the transaction. As a SPAC, Aimei Health is exposed to redemption risk, financing risk, and the possibility that trust-account funds are insufficient to support the post-combination company or required redemptions. More broadly, blank check companies face regulatory, market, and valuation risk because investor sentiment, capital-market conditions, and target-company quality can change quickly before closing.
The company has no operating business or revenue, so the announced merger is the primary path to becoming an operating company.
Exposure: Merger with United Hydrogen Group Inc.
The merger agreement can terminate if required approvals are not obtained or conditions are not satisfied by the deadline.
Exposure: Proposed United Hydrogen transaction
Public shareholders may redeem, reducing cash available from the trust account for the combined company.
Exposure: Trust account and post-close capitalization
Management notes that additional financing may be required to complete the business combination or fund redemptions.
Exposure: Deal financing and working capital
Accounting
Judgemental itemsCash held in trust is restricted and earns interest income, which drives reported earnings before a business combination closes.
Impact: Affects non-operating income, liquidity presentation, and shareholder redemption analysis
The $690,000 deferred fee is contingent on closing the business combination and must be tracked as a transaction-related obligation.
Impact: Impacts transaction costs and cash available at closing
Legal, audit, reporting, and due diligence expenses are the main recurring costs before the company becomes operational.
Impact: Drives quarterly net income volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Aimfinity Investment Corp. I
Blank Checks
Aimfinity Investment Corp.
Mountain Crest Acquisition Corp. V
MCAGU · Surgical & Medical Instruments & Apparatus
Mountain Crest Acquisition Corp.
NMP Acquisition Corp.
NMPAR · Blank Checks
AI Infrastructure Acquisition Corp.
AIIA-UN · Blank Checks
Voyager Acquisition Corp./Cayman Islands
Biological Products, (No Diagnostic Substances)
Voyager Acquisition Corp.
SIM Acquisition Corp. I
SIMAU · Blank Checks
SIM Acquisition Corp.
Last updated: 24/09/2026